U S. Medical Eligibility Criteria for Contraceptive Use, 2010.
CDC created U.S. Medical Eligibility Criteria for Contraceptive Use, 2010, from guidance developed by the World Health Organization (WHO) and finalized the recommendations after consultation with a group of health professionals who met in Atlanta, Georgia, during February 2009. This guidance comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. The majority of the U.S. guidance does not differ from the WHO guidance and covers >60 characteristics or medical conditions. However, some WHO recommendations were modified for use in the United States, including recommendations about contraceptive use for women with venous thromboembolism, valvular heart disease, ovarian cancer, and uterine fibroids and for postpartum and breastfeeding women. Recommendations were added to the U.S. guidance for women with rheumatoid arthritis, history of bariatric surgery, peripartum cardiomyopathy, endometrial hyperplasia, inflammatory bowel disease, and solid organ transplantation. The recommendations in this document are intended to assist health-care providers when they counsel women, men, and couples about contraceptive method choice. Although these recommendations are meant to serve as a source of clinical guidance, health-care providers should always consider the individual clinical circumstances of each person seeking family planning services.
Division of Reproductive Health, CDC, MS K-34, 4770 Buford Highway NE, Atlanta, GA 30341, USA.
D003267:Contraception / Q000379:methods*; D003270:Contraceptive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000075202:Contraindications; D004347:Drug Interactions; D004608:Eligibility Determination; D005260:Female; D006801:Humans; D008297:Male; D049168:Pregnancy, Unplanned; D014481:United States; D014944:World Health Organization
D003270:Contraceptive Agents